title: Ventricular tachycardia in valvular heart disease: facilitation of sustained bundle-branch reentry by valve surgery.
abstract: BACKGROUND
  The clinical characteristics of sustained monomorphic ventricular tachycardia (SMVT), when it develops after valve surgery, have not been described.
  
  
  RESULTS
  Between 1985 and 1996, 31 patients (30 men and 1 woman) who had undergone valve surgery were found to have inducible SMVT. Nine patients (29%) had sustained VT due to bundle-branch reentry (BBR) (group 1). Four of these patients had normal left ventricular function, and VT with a right bundle-branch morphology was inducible in 4 patients. Group 2 included 20 patients with inducible myocardial (ie, non-BBR) VT. Coronary artery disease was present in 15 group 2 patients (75%) due to atherosclerotic (n=12) and nonatherosclerotic (n=3) causes. Two patients had both inducible sustained BBR and myocardial VT (group 3). Sustained BBR VT occurred significantly earlier after valve surgery (median, 10 days) than the onset of postoperative myocardial VT (median, 72 months; P<.005).
  
  
  CONCLUSIONS
  Myocardial VT was the most common type of inducible SMVT in patients with valvular heart disease. The majority of these patients had underlying coronary artery disease and significant left ventricular dysfunction. However, in almost one third of the patients, sustained BBR VT was the only type of inducible SMVT. This type of VT was facilitated by the valve procedure occurring within 4 weeks after surgery in most patients. In these patients, left ventricular function was relatively well preserved, and the right bundle-branch block type of BBR was frequently induced. Because a curative therapy can be offered to these patients (ie, bundle-branch ablation), BBR should be seriously considered as the mechanism of VT in patients with valvular heart disease, particularly if the arrhythmia occurs soon after valve surgery.
authors.affiliation: Electrophysiology Laboratories, University of Wisconsin-Milwaukee Clinical Campus, Sinai Samaritan, Medical Center, USA.
authors.forename: C
authors.initials: C
authors.lastname: Narasimhan
authors.forename: M R
authors.initials: MR
authors.lastname: Jazayeri
authors.forename: J
authors.initials: J
authors.lastname: Sra
authors.forename: A
authors.initials: A
authors.lastname: Dhala
authors.forename: S
authors.initials: S
authors.lastname: Deshpande
authors.forename: M
authors.initials: M
authors.lastname: Biehl
authors.forename: M
authors.initials: M
authors.lastname: Akhtar
authors.forename: Z
authors.initials: Z
authors.lastname: Blanck
mesh_terms: D000328:Adult; D000368:Aged; D000638:Amiodarone / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D002036:Bundle of His / Q000503:physiopathology*; D017147:Defibrillators, Implantable; D004594:Electrophysiology; D005260:Female; D005500:Follow-Up Studies; D006349:Heart Valve Diseases / Q000150:complications* / Q000503:physiopathology / Q000601:surgery*; D006351:Heart Valves / Q000503:physiopathology / Q000601:surgery*; D006801:Humans; D008297:Male; D008875:Middle Aged; D017180:Tachycardia, Ventricular / Q000209:etiology* / Q000503:physiopathology
chemical_list: D000889:Anti-Arrhythmia Agents; D000638:Amiodarone